AOA Dx Funding Round

10/12/2023

Venture Equity

$17,000,000

Undisclosed

The company intends to use the funds to open new lab facilities, expand their ovarian cancer prospective clinical trial (OVERT) and develop the GlycoLocate� platform into various new cancer areas.

Private & Independent

Biopharmaceutical

Undisclosed
Boston, MA 02116
USA

AOA Dx Inc is a biotech company focused on early-stage cancer detection. AOA partnered with a leading oncology researcher at McGill University to develop the first early-stage ovarian cancer liquid biopsy diagnostic test. The co-founders have worked together for the last decade at two previous startups in the women's health space, both resulting in successful exits upon commercialization. Ovarian cancer is the deadliest gynecological disease because there is no accurate testing method and its symptoms are continuously mistaken for benign conditions, making it incredibly difficult to diagnose the disease in the early stages. Early diagnosis will reduce patient mortality and deliver cost savings to payers.